XML 44 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Note 13 - Equity Incentive Plan (Tables)
12 Months Ended
Dec. 31, 2019
Notes Tables  
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]
    December 31,
    2019   2018
Grants:        
Stock options    
254,517
     
199,970
 
RSAs    
-
     
64,578
 
RSUs    
189,507
     
15,457
 
PSUs    
123,500
     
-
 
Exercises:                
Stock options    
518,991
     
284,548
 
SARs    
35,250
     
-
 
Share-based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]
    2019
        Weighted
        Average
        Exercise
   
Number of
 
Price Per
   
Shares
 
Share
Options and SARs outstanding at beginning of year    
1,136,914
 
  $
42.06
 
Granted    
254,517
 
  $
41.92
 
Cancelled    
(97,575
)
  $
48.40
 
Expired    
(48,647
)
  $
51.18
 
Exercised    
(554,241
)
  $
40.37
 
Options and SARs outstanding at end of year    
690,968
 
  $
41.65
 
Schedule of Share-based Compensation, Exercisable Stock Options and Stock Appreciation Rights Award Activity [Table Text Bloc]
    Number
 Outstanding
  Weighted Avg
Exercise Price
  Weighted Average
Remaining Term
(in years)
Incentive stock options    
115,871
    $
22.90
     
3.7
 
Non-qualified stock options    
158,601
    $
38.82
     
5.8
 
Performance awards    
23,269
    $
46.51
     
6.6
 
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]
    2019
        Weighted
        Average
   
Number of
 
Grant Date
   
Shares
 
Fair Value
Unvested at Beginning of year    
59,083
 
  $
47.26
 
Granted    
313,007
 
  $
33.64
 
Cancelled    
(49,258
)
  $
34.65
 
Vested/Released    
(33,734
)
  $
48.39
 
Unvested at end of year    
289,098
 
  $
34.53
 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
    2019   2018   2017
Risk free interest rate  
1.41%
-
2.54%
 
2.15%
-
2.82%
 
1.60%
-
1.86%
Expected volatility  
44.27%
-
48.52%
 
37.12%
-
45.61%
 
38.74%
-
44.31%
Expected life (years)  
 
3.5
 
 
4.0
-
4.5
 
 
4.0
 
Expected dividend yield  
 
0.00%
 
 
 
0.00%
 
 
 
0.00%
 
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
    2019   2018   2017
Cost of product revenue   $
412
    $
(160
)   $
439
 
Research & development    
424
     
851
     
564
 
Selling, general & administrative    
5,251
     
10,355
     
4,804
 
Total stock-based compensation expense   $
6,087
    $
11,046
    $
5,807